CareDx Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx or view top-rated stocks.

Wall Street analysts have given CareDx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CareDx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for CareDx.

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings data on Thursday, July, 29th. The company reported ($0.04) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.05. The company had revenue of $74.19 million for the quarter, compared to analysts' expectations of $68.02 million. CareDx had a negative trailing twelve-month return on equity of 2.39% and a negative net margin of 3.53%.
View CareDx's earnings history.

CareDx's stock was trading at $18.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDNA stock has increased by 258.9% and is now trading at $67.97.
View which stocks have been most impacted by COVID-19.

CareDx issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $280 million-$290 million, compared to the consensus revenue estimate of $278.39 million.

6 analysts have issued 1-year price targets for CareDx's shares. Their forecasts range from $55.00 to $115.00. On average, they expect CareDx's share price to reach $96.17 in the next year. This suggests a possible upside of 41.5% from the stock's current price.
View analysts' price targets for CareDx or view top-rated stocks among Wall Street analysts.

Some companies that are related to CareDx include Guardant Health (GH), Natera (NTRA), Invitae (NVTA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL), Renalytix AI (RNLX), Celcuity (CELC) and Sera Prognostics (SERA).
View all of CDNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.95%), ARK Investment Management LLC (8.67%), BlackRock Inc. (8.03%), Invesco Ltd. (5.62%), Matrix Capital Management Company LP (3.31%) and Clearbridge Investments LLC (3.14%). Company insiders that own CareDx stock include George Bickerstaff, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends for CareDx.

CDNA stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, State Street Corp, FMR LLC, Balyasny Asset Management LLC, Ziegler Capital Management LLC, Credit Suisse AG, Nuveen Asset Management LLC, and Next Century Growth Investors LLC. Company insiders that have sold CareDx company stock in the last year include George Bickerstaff, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas, and William A Hagstrom.
View insider buying and selling activity for CareDx or view top insider-selling stocks.

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, Morgan Stanley, Morgan Stanley, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Conestoga Capital Advisors LLC, and ArrowMark Colorado Holdings LLC.
View insider buying and selling activity for CareDx or or view top insider-buying stocks.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDNA stock can currently be purchased for approximately $67.97.

CareDx has a market capitalization of $3.58 billion and generates $192.19 million in revenue each year. The company earns $-18,710,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

CareDx employs 466 workers across the globe.

The official website for CareDx is www.caredxinc.com.

CareDx is headquartered at 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (415) 287-2300 or via email at [email protected].